text: Direct factor Xa inhibitors are being used clinically and their usage is constantly increasing. They are gradually taking over warfarin usage and low molecular weight heparins (LMWH).  Indication for Xa inhibitors is preventing deep vein thrombosis (DVT) which can lead to pulmonary embolism. It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting (thrombosis) due to atherosclerosis. Rivaroxaban was the first FXa inhibitor on the market and then followed by apixaban, edoxaban and betrixaban.